$ADMA Class Alert: ADMA Biologics Investors May Have Rights in Pending Securities Fraud Class Action - Lead Plaintiff Deadline is August 10
Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice regarding ADMA Biologics, citing a pending class action over alleged securities fraud and channel stuffing. The firm alleges ADMA inflated 2025 growth figures to 20% despite waning demand, referencing a Culper Research report that triggered a significant stock decline in March 2026.
Key figures
- Stock drop march 24
- 16.6%
- Stock drop march 25
- 15%
- Stock drop march 29
- 13.9%
- Lead plaintiff deadline
- August 10, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.